Ref ID: 18672
Author:
S. Husain, MD – Associate Professor of Medicine, L. Singer, MD – Medical Director, Toronto Lung Transplant Program, Y. Akinlolu, MSc – Clinical Research Coordinator, C. Chaparro, MD – Assistant Professor of Medicine, C. Rotstein, MD – Professor of Me
Author address:
Univ. Hlth. Network, Toronto, Canada.
Full conference title:
52nd Annual ICAAC
Date: 9 September 2014
Abstract:
Background: LTRs have the highest incidence of Invasive Aspergillosis (IA) among solid organ transplant recipients. This higher rate has prompted the adoption of a universal antifungal prophylaxis approach in most of the lung transplant centers around the world. We assessed the utility of PET based on the incorporation of BAL GM and culture methods for the initiation of antifungal therapy. Methods: We evaluated 91 consecutive LTRs since January 2010 with at least 12 months of follow-up. Antifungal PET was instituted if the patients were known to be colonized with Aspergillus (ASP) prior to transplantation, had positive GM or positive culture for ASP at time of bronchoscopy during the first year of transplant. EORTC/MSG/ISHLT criteria were used to define the type of invasive fungal infections. Results: A total of 399 BALs were performed in these patients. The distribution of positive and negative GM samples and invasive fugal syndromes are shown below: A total of 51 (PretxASP col, 14; GM+, 31; PosttxASP culture+, 6) patients received PET with antimold agents. No cases of IA were identified in patients who did not satisfy PET criteria. Conclusions: PET based on the synergistic use of BAL GM and culture in LTRs during the first year decreased the use of anti-fungal therapy by 43% without missing any cases of IA.
Abstract Number: T-1067
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a